Abstract
Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Current Pharmaceutical Biotechnology
Title: Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Volume: 5 Issue: 6
Author(s): Jeff W. M. Bulte and Dara L. Kraitchman
Affiliation:
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Abstract: Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Export Options
About this article
Cite this article as:
M. Bulte W. Jeff and Kraitchman L. Dara, Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents, Current Pharmaceutical Biotechnology 2004; 5 (6) . https://dx.doi.org/10.2174/1389201043376526
DOI https://dx.doi.org/10.2174/1389201043376526 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists
Current Pharmaceutical Design Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
Current Medicinal Chemistry Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis
Anti-Cancer Agents in Medicinal Chemistry What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets The Zebrafish as a Novel Tool for Cardiovascular Drug Discovery
Recent Patents on Cardiovascular Drug Discovery Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued)